Neoadjuvant chemotherapy and intratumoral T-cell density

Acredit’s Vegar Johansen Dagenborg has published a paper called “Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases”. Vegar’s research found that patients with microsatellite stable (MSS) status who had received neoadjuvant chemotherapy were more likely to experience a temporary increase in the density of T-cells inside the tumour itself. Vegar’s work suggests that there may be benefits to be gained in the appropriate and timely scheduling of treatment for patients when using cytotoxic chemotherapy with immune checkpoint inhibition for colorectal liver metastases.

Vegar’s paper may be read here.